Process R&D Services
Scalable Process Development Driven by Quality and Compliance
At PI Health Sciences, our Process R&D Services provide end-to-end development support for GMP and non-GMP APIs, KSMs, and RSMs, spanning preclinical toxicology batches through commercial manufacturing. We design, optimize, and scale synthetic routes with a structured focus on safety, quality, and operational efficiency. Our phase-appropriate development approach ensures seamless transition from early-stage research to validated, scalable processes ready for downstream manufacturing.
Our Process R&D model integrates scientific rigor with operational discipline. This includes route scouting and optimization, salt and polymorph screening, impurity synthesis, and stability evaluation to strengthen process robustness. Advanced reaction capabilities, including chiral synthesis and complex organometallic transformations, are supported by integrated safety assessments and structured scale-up strategies to minimize technical risk prior to transfer.
Execution is reinforced through cross-functional collaboration across IP, QA, DQA, EHS, SCM, and regulatory teams to ensure regulatory alignment and supply readiness. Emphasis on green chemistry principles, process efficiency, and early risk mitigation enables sustainable and commercially viable manufacturing solutions across the product lifecycle.
Capabilities
Phase Appropriate Development
We design phase-specific synthetic processes aligned to preclinical, clinical, and commercial needs, ensuring regulatory readiness at each stage. Process intensification, optimization, and validation are structured for reproducibility, scalable chemistry, and seamless GMP technology transfer.
Synthetic Route Design
Our scientists design and optimize convergent and linear synthetic routes using mechanistic and kinetic insights. Capabilities include chiral synthesis, organometallic transformations, and reaction optimization to improve yield, selectivity, and process efficiency while minimizing impurities.
Solid State & Impurity Science
We perform salt screening, polymorph characterization, and solid-state stability studies to ensure manufacturability and regulatory compliance. Impurity profiling, forced degradation, and stability programs generate robust data to support regulatory submissions.
Regulatory Governance
Process safety assessments are conducted pre scale up with integrated hazard analysis and risk mitigation. Cross functional alignment across IP, QA, DQA, EHS, SCM, and Regulatory ensures global compliance, supported by OEB4 containment and strict safety protocols.
Operational Infrastructure
End to end lifecycle management is supported by automated labs and digital monitoring systems. Global facilities in India and Italy enable flexible, regulatory-aligned execution, while integrated vendor networks ensure secure supply chains and consistent development continuity.
Frequently asked questions
We’re here to help with any questions you have about our plans, supported features, and how our model works.
What stages of development do Process R&D Services cover?
PI Health Sciences, Process R&D Services support the full development lifecycle, beginning with preclinical toxicology batches and extending through commercial scale manufacturing. Our expertise spans GMP and non GMP production of APIs, KSMs, and RSMs, ensuring continuity across early research, clinical development, and market supply. Each development phase is approached with a phase appropriate strategy. Early stage programs focus on robust route scouting, feasibility assessment, and impurity understanding, while later stages prioritize process validation, scalability, regulatory alignment, and lifecycle management. This structured progression enables smooth transitions between phases without compromising quality, safety, or efficiency.
Does PI Health Sciences support high potency compounds?
PI Health Sciences offers high potency handling capabilities up to OEB4, supported by specialized infrastructure and safety focused operational practices. Our teams are experienced in managing challenging chemistries while maintaining stringent safety standards and regulatory compliance. High potency process development requires disciplined containment strategies, controlled environments, and precise operational planning. Our integrated approach ensures that safety, quality, and efficiency remain aligned throughout development and scale up activities.
How does PI Health Sciences ensure seamless scale up?
Seamless scale up is achieved through structured phase specific development strategies and early route optimization. By designing scalable synthetic pathways from the outset, we reduce technical risks associated with transition from laboratory scale to pilot and commercial production. Integrated safety studies are conducted prior to scale expansion to evaluate process robustness and mitigate operational risks. Cross functional collaboration across IP, QA, DQA, EHS, SCM, and RA teams ensures alignment between technical development, regulatory expectations, and supply chain readiness. This comprehensive preparation supports efficient technology transfer and consistent process performance at larger scales.
What differentiates our Process R&D model?
Our Process R&D model is built on integration, scientific rigor, and operational discipline. We combine route scouting, synthetic optimization, impurity synthesis, stability studies, and salt and polymorph screening within a unified development framework. Cross functional support from IP, QA, DQA, EHS, SCM, and RA functions ensures that technical development remains aligned with regulatory and commercial objectives. Proactive anticipation of regulatory challenges strengthens submission readiness and reduces downstream delays. Vendor engagement strategies further enhance raw material reliability and cost competitiveness. This structured, integrated approach enables consistent quality, regulatory confidence, and scalable process performance.